Duzkopru Yakup, Kocanoglu Abdulkadir, Dogan Ozlem, Sahinli Hayriye, Cilbir Ebru, Altinbas Mustafa
Department of Medical Oncology, Ankara Etlik City Hospital, Ankara 06170, Turkey.
World J Gastrointest Oncol. 2023 Sep 15;15(9):1626-1635. doi: 10.4251/wjgo.v15.i9.1626.
The hemoglobin, albumin, lymphocyte, and platelet (HALP) score, derived from a composite evaluation of markers reflecting the tumor-inflammation relationship and nutritional status, has been substantiated as a noteworthy prognostic determinant for diverse malignancies.
To investigate how the HALP score relates to prognosis in patients with metastatic gastric cancer.
The cutoff values for the HALP score, neutrophil/lymphocyte ratio, and platelet/lymphocyte ratio were determined using receiver operating characteristic analysis. Low HALP scores were defined as those less than 24.79 and high HALP scores as those greater than 24.79.
The study cohort comprised 147 patients and 110 of them (74.8%) were male. The patients' median age was 63 (22-89) years. The median overall survival was significantly superior in the patients with high HALP scores than in those with low HALP scores (10.4 mo 7.5 mo, respectively; < 0.001).
The HALP score was found to be a prognostic factor in patients with metastatic gastric cancer.
血红蛋白、白蛋白、淋巴细胞和血小板（HALP）评分源自对反映肿瘤-炎症关系和营养状况的标志物的综合评估，已被证实是多种恶性肿瘤值得关注的预后决定因素。
探讨HALP评分与转移性胃癌患者预后的关系。
采用受试者工作特征分析确定HALP评分、中性粒细胞/淋巴细胞比值和血小板/淋巴细胞比值的临界值。HALP评分低定义为低于24.79，HALP评分高定义为高于24.79。
研究队列包括147例患者，其中110例（74.8%）为男性。患者的中位年龄为63（22-89）岁。HALP评分高的患者中位总生存期显著优于HALP评分低的患者（分别为10.4个月和7.5个月；P<0.001）。
HALP评分是转移性胃癌患者的一个预后因素。
